EAA clinical practice guidelines-gynecomastia evaluation and management.
Adolescent
Adult
Androgens
/ therapeutic use
Aromatase Inhibitors
/ therapeutic use
Breast
/ diagnostic imaging
Breast Neoplasms, Male
/ diagnosis
Gynecomastia
/ diagnosis
Humans
Infant
Infant, Newborn
Lipoma
/ diagnosis
Male
Practice Guidelines as Topic
Selective Estrogen Receptor Modulators
/ therapeutic use
Testicular Neoplasms
/ diagnosis
Testosterone
/ deficiency
diagnosis
gynecomastia
male breast cancer
management
testosterone
Journal
Andrology
ISSN: 2047-2927
Titre abrégé: Andrology
Pays: England
ID NLM: 101585129
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
31
03
2019
accepted:
01
04
2019
pubmed:
18
5
2019
medline:
4
8
2020
entrez:
18
5
2019
Statut:
ppublish
Résumé
Gynecomastia (GM) is a benign proliferation of the glandular tissue of the breast in men. It is a frequent condition with a reported prevalence of 32-65%, depending on the age and the criteria used for definition. GM of infancy and puberty are common, benign conditions resolving spontaneously in the majority of cases. GM of adulthood is more prevalent among the elderly and proper investigation may reveal an underlying pathology in 45-50% of cases. The aim was to provide clinical practice guidelines for the evaluation and management of GM. A literature search of articles in English for the term 'gynecomastia' was conducted. Evidence-based recommendations were developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system. A set of five statements and fifteen clinical recommendations was formulated. The purpose of GM assessment should be the detection of underlying pathological conditions, reversible causes (administration/abuse of aggravating substances), and the discrimination from other breast lumps, particularly breast cancer. Assessment should comprise a thorough medical history and physical examination of the breast and genitalia (including testicular ultrasound). A set of laboratory investigations may integrate the evaluation: testosterone (T), estradiol (E2), sex hormone-binding globulin (SHBG), luteinizing hormone (LH), follicular stimulating hormone (FSH), thyroid stimulating hormone (TSH), prolactin, human chorionic gonadotropin (hCG), alpha-fetal protein (AFP), liver and renal function tests. Breast imaging may be used whenever the clinical examination is equivocal. In suspicious lesions, core needle biopsy should be sought directly instead. Watchful waiting is recommended after treatment of underlying pathology or discontinuation of substances associated with GM. T treatment should be offered to men with proven T deficiency. The use of selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs) and non-aromatizable androgens is not justified in general. Surgical treatment is the therapy of choice for patients with long-lasting GM. S1. Gynecomastia (GM) is a benign proliferation of glandular tissue of the breast in males. S2. GM of infancy is a common condition that usually resolves spontaneously, typically within the first year of life. S3. GM of puberty is a common condition, affecting approximately 50% of mid-pubertal boys; in more than 90% of cases, it resolves spontaneously within 24 months. S4. The prevalence of GM in adulthood increases with increasing age; proper investigation may reveal an underlying pathology in approximately 45-50% of the cases. S5. Male breast cancer is rare; GM should not be considered a premalignant condition. The following recommendations are divided into 'strong', denoted by the number 1 and associated with the terminology 'we recommend', and 'weak' denoted by the number 2 and associated with the phrase 'we suggest'. The grading of the quality of evidence is denoted as follows: ⊕○○○ for very low-quality evidence; ⊕⊕○○ for low quality; ⊕⊕⊕○ for moderate quality; and ⊕⊕⊕⊕ for high quality. R1. The presence of an underlying pathology should be considered in GM of adulthood. We recommend that the identification of an apparent reason for GM in adulthood, including the use of medication known to be associated with GM, should not preclude a detailed investigation (1 ⊕⊕⊕○). R2. We suggest that the initial screening to rule out lipomastia, obvious breast cancer, or testicular cancer might be performed by a general practitioner or another non-specialist (2 ⊕○○○). R3. We recommend that in those cases where a thorough diagnostic workup is warranted, it should be performed by a specialist (1 ⊕○○○). R4. We recommend that the medical history should include information on the onset and duration of GM, sexual development and function, and administration or abuse of substances associated with GM (1 ⊕⊕⊕○). R5. We recommend that the physical examination should detect signs of under-virilization or systemic disease (1 ⊕⊕⊕⊕). R6. We recommend that breast examination should confirm the presence of palpable glandular tissue to discriminate GM from lipomastia (pseudo-gynecomastia) and rule out the suspicion of malignant breast tumor (1 ⊕⊕⊕⊕). R7. We recommend that the physical examination should include the examination of the genitalia to rule out the presence of a palpable testicular tumor and to detect testicular atrophy (1 ⊕⊕⊕⊕). R8. We recommend that genitalia examination is aided by a testicular ultrasound, as the detection of a testicular tumor by palpation has low sensitivity (1 ⊕⊕○○). R9. We suggest that a set of evaluations may include T, E
Sections du résumé
BACKGROUND
Gynecomastia (GM) is a benign proliferation of the glandular tissue of the breast in men. It is a frequent condition with a reported prevalence of 32-65%, depending on the age and the criteria used for definition. GM of infancy and puberty are common, benign conditions resolving spontaneously in the majority of cases. GM of adulthood is more prevalent among the elderly and proper investigation may reveal an underlying pathology in 45-50% of cases.
OBJECTIVES
The aim was to provide clinical practice guidelines for the evaluation and management of GM.
MATERIALS AND METHODS
A literature search of articles in English for the term 'gynecomastia' was conducted. Evidence-based recommendations were developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system.
RESULTS
A set of five statements and fifteen clinical recommendations was formulated.
CONCLUSIONS
The purpose of GM assessment should be the detection of underlying pathological conditions, reversible causes (administration/abuse of aggravating substances), and the discrimination from other breast lumps, particularly breast cancer. Assessment should comprise a thorough medical history and physical examination of the breast and genitalia (including testicular ultrasound). A set of laboratory investigations may integrate the evaluation: testosterone (T), estradiol (E2), sex hormone-binding globulin (SHBG), luteinizing hormone (LH), follicular stimulating hormone (FSH), thyroid stimulating hormone (TSH), prolactin, human chorionic gonadotropin (hCG), alpha-fetal protein (AFP), liver and renal function tests. Breast imaging may be used whenever the clinical examination is equivocal. In suspicious lesions, core needle biopsy should be sought directly instead. Watchful waiting is recommended after treatment of underlying pathology or discontinuation of substances associated with GM. T treatment should be offered to men with proven T deficiency. The use of selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs) and non-aromatizable androgens is not justified in general. Surgical treatment is the therapy of choice for patients with long-lasting GM.
SUMMARY OF STATEMENTS (S) AND RECOMMENDATIONS (R)
S1. Gynecomastia (GM) is a benign proliferation of glandular tissue of the breast in males. S2. GM of infancy is a common condition that usually resolves spontaneously, typically within the first year of life. S3. GM of puberty is a common condition, affecting approximately 50% of mid-pubertal boys; in more than 90% of cases, it resolves spontaneously within 24 months. S4. The prevalence of GM in adulthood increases with increasing age; proper investigation may reveal an underlying pathology in approximately 45-50% of the cases. S5. Male breast cancer is rare; GM should not be considered a premalignant condition. The following recommendations are divided into 'strong', denoted by the number 1 and associated with the terminology 'we recommend', and 'weak' denoted by the number 2 and associated with the phrase 'we suggest'. The grading of the quality of evidence is denoted as follows: ⊕○○○ for very low-quality evidence; ⊕⊕○○ for low quality; ⊕⊕⊕○ for moderate quality; and ⊕⊕⊕⊕ for high quality. R1. The presence of an underlying pathology should be considered in GM of adulthood. We recommend that the identification of an apparent reason for GM in adulthood, including the use of medication known to be associated with GM, should not preclude a detailed investigation (1 ⊕⊕⊕○). R2. We suggest that the initial screening to rule out lipomastia, obvious breast cancer, or testicular cancer might be performed by a general practitioner or another non-specialist (2 ⊕○○○). R3. We recommend that in those cases where a thorough diagnostic workup is warranted, it should be performed by a specialist (1 ⊕○○○). R4. We recommend that the medical history should include information on the onset and duration of GM, sexual development and function, and administration or abuse of substances associated with GM (1 ⊕⊕⊕○). R5. We recommend that the physical examination should detect signs of under-virilization or systemic disease (1 ⊕⊕⊕⊕). R6. We recommend that breast examination should confirm the presence of palpable glandular tissue to discriminate GM from lipomastia (pseudo-gynecomastia) and rule out the suspicion of malignant breast tumor (1 ⊕⊕⊕⊕). R7. We recommend that the physical examination should include the examination of the genitalia to rule out the presence of a palpable testicular tumor and to detect testicular atrophy (1 ⊕⊕⊕⊕). R8. We recommend that genitalia examination is aided by a testicular ultrasound, as the detection of a testicular tumor by palpation has low sensitivity (1 ⊕⊕○○). R9. We suggest that a set of evaluations may include T, E
Substances chimiques
Androgens
0
Aromatase Inhibitors
0
Selective Estrogen Receptor Modulators
0
Testosterone
3XMK78S47O
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
778-793Informations de copyright
© 2019 American Society of Andrology and European Academy of Andrology.
Références
Akgül S, Kanbur N & Derman O. (2014) Pubertal gynecomastia: what about the remaining 10%? J Pediatr Endocrinol Metab 27, 1027-1028.
Alesini D, Iacovelli R, Palazzo A, Altavilla A, Risi E, Urbano F, Manai C, Passaro A, Magri V & Cortesi E. (2013) Multimodality treatment of gynecomastia in patients receiving antiandrogen therapy for prostate cancer in the era of abiraterone acetate and new antiandrogen molecules. Oncology 84, 92-99.
Ashkar FS, Smoak WM, Gilson AJ & Miller R. (1970) Gynecomastia and mastoplasia in Graves’ disease. Metabolism 19, 946-951.
Avci A, Erol B, Eken C & Ozgok Y. (2008) Nine cases of nonpalpable testicular mass: an incidental finding in a large scale ultrasonography survey. Int J Urol 15, 833-836.
Bannayan GA & Hajdu SI. (1972) Gynecomastia: clinicopathologic study of 351 cases. Am J Clin Pathol 57, 431-437.
Benveniste O, Simon A & Herson S. (2001) Successful percutaneous dihydrotestosterone treatment of gynecomastia occurring during highly active antiretroviral therapy: four cases and a review of the literature. Clin Infect Dis 33, 891-893.
Bercovici JP, Tater D, Khoury S, Charles JF, Floch J & Leroy JP. (1981) Leydig cell tumor with gynecomastia: hormonal effects of an estrogen-producing tumor. J Clin Endocrinol Metab 53, 1291-1296.
Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM & Task Force, Endocrine Society. (2018) Task Force, Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 103, 1-30.
Biesma HD, Schouten PC, Lacle MM, Sanders J, Brugman W, Kerkhoven R, Mandjes I, van der Groep P, van Diest PJ & Linn SC. (2015) Copy number profiling by array comparative genomic hybridization identifies frequently occurring BRCA2-like male breast cancer. Genes Chromosom Cancer 54, 734-744.
Biro FM, Lucky AW, Huster GA & Morrison JA. (1990) Hormonal studies and physical maturation in adolescent gynecomastia. J Pediatr 116, 450-455.
Boccardo F, Rubagotti A, Battaglia M, Di Tonno P, Selvaggi FP, Conti G, Comeri G, Bertaccini A, Martorana G, Galassi P, Zattoni F, Macchiarella A, Siragusa A, Muscas G, Durand F, Potenzoni D, Manganelli A, Ferraris V & Montefiore F. (2005) Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol 23, 808-815.
Boddi V, Barbaro V, McNieven P, Maggi M & Rotella CM. (2014) Present and future association between obesity and hypogonadism in Italian male. Arch Ital Di Urol E Androl 86, 26-32.
Boljanovic S, Axelsson CK & Elberg JJ. (2003) Surgical treatment of gynecomastia: liposuction combined with subcutaneous mastectomy. Scand J Surg 92, 160-162.
Braunstein GD. (1999) Aromatase and gynecomastia. Endocr Relat Cancer 6, 315-324.
Braunstein GD. (2007) Gynecomastia. N Engl J Med 357, 1229-1237.
Brinton LA. (2011) Breast cancer risk among patients with Klinefelter syndrome. Acta Paediatr 100, 814-818.
Carmignani L, Gadda F, Gazzano G, Nerva F, Mancini M, Ferruti M, Bulfamante G, Bosari S, Coggi G, Rocco F & Colpi GM. (2003) High incidence of benign testicular neoplasms diagnosed by ultrasound. J Urol 170, 1783-1786.
Castilla-García A, Santolaria-Fernández FJ, González-Reimers CE, Batista-López N, González-García C, Jorge-Hernández JA & Hernández-Nieto L. (1987) Alcohol-induced hypogonadism: reversal after ethanol withdrawal. Drug Alcohol Depend 20, 255-260.
Cavanaugh J, Niewoehner CB & Nuttall FQ. (1990) Gynecomastia and cirrhosis of the liver. Arch Intern Med 150, 563-565.
Chapman N, Dobson J, Wilson S & Anglo-Scandinavian Cardiac Outcomes Trial Investigators. (2007) Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49, 839-845.
Chau A, Jafarian N & Rosa M. (2016) Male breast: clinical and imaging evaluations of benign and malignant entities with histologic correlation. Am J Med 129, 776-791.
Christou MA, Christou PA, Markozannes G, Tsatsoulis A, Mastorakos G & Tigas S. (2017) Effects of anabolic androgenic steroids on the reproductive system of athletes and recreational users: a systematic review and meta-analysis. Sports Med 47, 1869-1883.
De Barros ACSD & Sampaio MDCM. (2012) Gynecomastia: physiopathology, evaluation and treatment. Sao Paulo Med J 130, 187-197.
Dejager S, Bry-Gauillard H, Bruckert E, Eymard B, Salachas F, LeGuern E, Tardieu S, Chadarevian R, Giral P & Turpin G. (2002) A comprehensive endocrine description of Kennedy's disease revealing androgen insensitivity linked to CAG repeat length. J Clin Endocrinol Metab 87, 3893-3901.
Derman O, Kanbur NO & Kutluk T. (2003) Tamoxifen treatment for pubertal gynecomastia. Int J Adolesc Med Health 15, 359-363.
Dicker AP. (2003) The safety and tolerability of low-dose irradiation for the management of gynaecomastia caused by antiandrogen monotherapy. Lancet Oncol 4, 30-36.
DiRaimondo CV, Roach AC & Meador CK. (1980) Gynecomastia from exposure to vaginal estrogen cream. N Engl J Med 302, 1089-1090.
Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE & Mazer NA. (1999) Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 84, 3469-3478.
Dobs A & Darkes MJM. (2005) Incidence and management of gynecomastia in men treated for prostate cancer. J Urol 174, 1737-1742.
Eberle AJ, Sparrow JT & Keenan BS. (1986) Treatment of persistent pubertal gynecomastia with dihydrotestosterone heptanoate. J Pediatr 109, 144-149.
Einav-Bachar R, Phillip M, Aurbach-Klipper Y & Lazar L. (2004) Prepubertal gynaecomastia: aetiology, course and outcome. Clin Endocrinol (Oxf) 61, 55-60.
Fentiman IS, Fourquet A & Hortobagyi GN. (2006) Male breast cancer. Lancet 367, 595-604.
Ferreira M, Mesquita M, Quaresma M & André S. (2008) Prolactin receptor expression in gynaecomastia and male breast carcinoma. Histopathology 53, 56-61.
Forest MG, Lecoq A & Saez JM. (1979) Kinetics of human chorionic gonadotropin-induced steroidogenic response of the human testis. II. Plasma 17 alpha-hydroxyprogesterone, delta4-androstenedione, estrone, and 17 beta-estradiol: evidence for the action of human chorionic gonadotropin on interm. J Clin Endocrinol Metab 49, 284-291.
Georgiadis E, Papandreou L, Evangelopoulou C, Aliferis C, Lymberis C, Panitsa C & Batrinos M. (1994) Incidence of gynaecomastia in 954 young males and its relationship to somatometric parameters. Ann Hum Biol 21, 579-587.
Geyer H, Schänzer W & Thevis M. (2014) Anabolic agents: recent strategies for their detection and protection from inadvertent doping. Br J Sports Med 48, 820-826.
Giampietro PG, Bruno G, Furcolo G, Casati A, Brunetti E, Spadoni GL & Galli E. (2004) Soy protein formulas in children: no hormonal effects in long-term feeding. J Pediatr Endocrinol Metab 17, 191-196.
Gottlieb B, Beitel LK, Nadarajah A, Paliouras M & Trifiro M. (2012) The androgen receptor gene mutations database: 2012 update. Hum Mutat 33, 887-894.
Grigg J, Worsley R, Thew C, Gurvich C, Thomas N & Kulkarni J. (2017) Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research. Psychopharmacology 234, 3279-3297.
Gudin JA, Laitman A & Nalamachu S. (2015) Opioid related endocrinopathy: Table 1. Pain Med 16(suppl 1), S9-S15.
Handelsman DJ & Dong Q. (1993) Hypothalamo-pituitary gonadal axis in chronic renal failure. Endocrinol Metab Clin North Am 22, 145-161.
Handelsman D, Newman JD, Jimenez M, McLachlan R, Sartorius G & Jones GRD. (2014) Performance of direct estradiol immunoassays with human male serum samples. Clin Chem 60, 510-517.
Harmon J & Aliapoulios MA. (1972) Gynecomastia in marihuana users. N Engl J Med 287, 936.
Hellmann P, Christiansen P, Johannsen TH, Main KM, Duno M & Juul A. (2012) Male patients with partial androgen insensitivity syndrome: a longitudinal follow-up of growth, reproductive hormones and the development of gynaecomastia. Arch Dis Child 97, 403-409.
Henley DV, Lipson N, Korach KS & Bloch CA. (2007) Prepubertal gynecomastia linked to lavender and tea tree oils. N Engl J Med 356, 479-485.
Hines SL, Tan WW, Yasrebi M, DePeri ER & Perez EA. (2007) The role of mammography in male patients with breast symptoms. Mayo Clin Proc 82, 297-300.
Hou SH, Grossman S & Molitch ME. (1985) Hyperprolactinemia in patients with renal insufficiency and chronic renal failure requiring hemodialysis or chronic ambulatory peritoneal dialysis. Am J Kidney Dis 6, 245-249.
Huhtaniemi IT, Tajar A, Lee DM, O'Neill TW, Finn JD, Bartfai G & EMAS Group. (2012) Comparison of serum testosterone and estradiol measurements in 3174 European men using platform immunoassay and mass spectrometry; relevance for the diagnostics in aging men. Eur J Endocrinol 166, 983-991.
Iglesias P, Carrero JJ & Díez JJ. (2012) Gonadal dysfunction in men with chronic kidney disease: clinical features, prognostic implications and therapeutic options. J Nephrol 25, 31-42.
Ismail AA & Barth JH. (2001) Endocrinology of gynaecomastia. Ann Clin Biochem 38, 596-607.
Jacobs EC. (1948) Effects of starvation on sex hormones in the male. J Clin Endocrinol Metab 8, 227-232.
James R, Ahmed F & Cunnick G. (2012) The efficacy of tamoxifen in the treatment of primary gynecomastia: an observational study of tamoxifen versus observation alone. Breast J 18, 620-621.
Jayasinghe Y, Cha R, Horn-Ommen J, O'Brien P & Simmons PS. (2010) Establishment of normative data for the amount of breast tissue present in healthy children up to two years of age. J Pediatr Adolesc Gynecol 23, 305-311.
Kaltsas G, Kanakis G & Chrousos G. (2000) Carney's Complex. Endotext.
Kanhai RC, Hage JJ, van Diest PJ, Bloemena E & Mulder JW. (2000) Short-term and long-term histologic effects of castration and estrogen treatment on breast tissue of 14 male-to-female transsexuals in comparison with two chemically castrated men. Am J Surg Pathol 24, 74-80.
Kasielska A & Antoszewski B. (2011) Effect of operative treatment on psychosocial problems of men with gynaecomastia. Pol Przegl Chir 83, 614-621.
Khan HN, Rampaul R & Blamey RW. (2004) Management of physiological gynaecomastia with tamoxifen. Breast 13, 61-65.
Kidd GS, Glass AR & Vigersky RA. (1979) The hypothalamic-pituitary-testicular axis in thyrotoxicosis. J Clin Endocrinol Metab 48, 798-802.
Kilic M, Kanbur N, Derman O, Akgül S & Kutluk T. (2011) The relationship between pubertal gynecomastia, prostate specific antigen, free androgen index, SHBG and sex steroids. J Pediatr Endocrinol Metab 24, 61-67.
Kinsella C, Landfair A, Rottgers SA, Cray JJ, Weidman C, Deleyiannis FW-B, Grunwaldt L & Losee JE. (2012) The psychological burden of idiopathic adolescent gynecomastia. Plast Reconstr Surg 129, 1-7.
Knorr D & Bidlingmaier F. (1975) Gynaecomastia in male adolescents. Clin Endocrinol Metab 4, 157-171.
Krassas GE, Poppe K & Glinoer D. (2010) Thyroid function and human reproductive health. Endocr Rev 31, 702-755.
Krause W (2012) Drug-inducing gynaecomastia - a critical review. Andrologia 44(Suppl.1), 621-626.
Kuhn JM, Roca R, Laudat M, Rieu M, Luton J & Bricaire H. (1983) Studies on the treatment of idiopathic gynaecomastia with percutaneous dihydrotestosterone. Clin Endocrinol (Oxf) 19, 513-520.
Kumanov P, Deepinder F, Robeva R, Tomova A, Li J & Agarwal A. (2007) Relationship of adolescent gynecomastia with varicocele and somatometric parameters: a cross-sectional study in 6200 healthy boys. J Adolesc Health 41, 126-131.
La Spada AR, Roling DB, Harding AE, Warner CL, Spiegel R, Hausmanowa-Petrusewicz I, Yee WC & Fischbeck KH. (1992) Meiotic stability and genotype-phenotype correlation of the trinucleotide repeat in X-linked spinal and bulbar muscular atrophy. Nat Genet 2, 301-304.
LaFemina J & Brennan MF. (2012) Adrenocortical carcinoma: past, present, and future. J Surg Oncol 106, 586-594.
Laitman Y, Keinan Boker L, Liphsitz I, Weissglas-Volkov D, Litz-Philipsborn S, Schayek H & Friedman E. (2015) Cancer risks in Jewish male BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 150, 631-635.
Lawrence SE, Faught KA, Vethamuthu J & Lawson ML. (2004) Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia. J Pediatr 145, 71-76.
Lee PA. (1975) The relationship of concentrations of serum hormones to pubertal gynecomastia. J Pediatr 86, 212-215.
Lee KO, Chua DY & Cheah JS. (1990) Oestrogen and progesterone receptors in men with bilateral or unilateral pubertal macromastia. Clin Endocrinol (Oxf) 32, 101-105.
Letterman G & Schurter M. (1976) A comparison of modern methods of reduction mammaplasty. South Med J 69, 1367-1371.
Lotti F & Maggi M. (2015) Ultrasound of the male genital tract in relation to male reproductive health. Hum Reprod Update 21, 56-83.
Madlon-Kay DJ. (1986) Witch”s milk. Am J Dis Child 140, 252.
Marshall WA & Tanner JM. (1969) Variations in pattern of pubertal changes in girls. Arch Dis Child 44, 291-303.
Maruyama Y, Adachi Y, Aoki N, Suzuki Y, Shinohara H & Yamamoto T. (1991) Mechanism of feminization in male patients with non-alcoholic liver cirrhosis: role of sex hormone-binding globulin. Gastroenterol Jpn 26, 435-439.
Mathur R & Braunstein GD. (1997) Gynecomastia: pathomechanisms and treatment strategies. Horm Res 48, 95-102.
Matsumoto A & Bremner W. (2011) Male Hypogonadism. In: Williams Textbook of Endocrinology, 12th edn (eds S Melmed, K Polonsky, P Larsen & H Kroneneberg), pp. 709-755. Saunders, Philadelphia.
Mauras N, Bishop K, Merinbaum D, Emeribe U, Agbo F & Lowe E. (2009) Pharmacokinetics and pharmacodynamics of anastrozole in pubertal boys with recent-onset gynecomastia. J Clin Endocrinol Metab 94, 2975-2978.
McDermott MT, Hofeldt FD & Kidd GS. (1990) Tamoxifen therapy for painful idiopathic gynecomastia. South Med J 83, 1283-1285.
McKiernan JF & Hull D. (1981) Breast development in the newborn. Arch Dis Child 56, 525-529.
Mendelson JH, Kuehnle J, Ellingboe J & Babor TF. (1974) Plasma testosterone levels before, during and after chronic marihuana smoking. N Engl J Med 291, 1051-1055.
Mieritz MG, Rakêt LL, Hagen CP, Nielsen JE, Talman M-LM, Petersen JH, Sommer SH, Main KM, Jørgensen N & Juul A. (2015) A longitudinal study of growth, sex steroids, and IGF-1 in boys with physiological gynecomastia. J Clin Endocrinol Metab 100, 3752-3759.
Mieritz MG, Christiansen P, Jensen MB, Joensen UN, Nordkap L, Olesen IA, Bang AK, Juul A & Jørgensen N. (2017) Gynaecomastia in 786 adult men: clinical and biochemical findings. Eur J Endocrinol 176, 555-566.
Moore DC, Schlaepfer LV, Paunier L & Sizonenko PC. (1984) Hormonal changes during puberty: V. transient pubertal gynecomastia: abnormal androgen-estrogen ratios. J Clin Endocrinol Metab 58, 492-499.
Morales A, Collier CP & Clark AF. (2012) A critical appraisal of accuracy and cost of laboratory methodologies for the diagnosis of hypogonadism: the role of free testosterone assays. Can J Urol 19, 6314-6318.
Muñoz Carrasco R, Alvarez Benito M, Muñoz Gomariz E, Raya Povedano JL & Martínez PM. (2010) Mammography and ultrasound in the evaluation of male breast disease. Eur Radiol 20, 2797-2805.
Nachtigall C. (1965) Progress observations on physiological swelling of the breast in newborn infants. Monatsschr Kinderheilkd 113, 497-498.
Narula HS & Carlson HE. (2014) Gynaecomastia-pathophysiology, diagnosis and treatment. Nat Rev Endocrinol 10, 684-698.
Nichols CR, Heerema NA, Palmer C, Loehrer PJ, Williams SD & Einhorn LH. (1987) Klinefelter's syndrome associated with mediastinal germ cell neoplasms. J Clin Oncol 5, 1290-1294.
Nicolis GL, Modlinger RS & Lester GJ. (1971) A study of the histopathology of human gynecomastia. J Clin Endocrinol Metab 32, 173-178.
Nieschlag E & Vorona E. (2015) Mechanisms in Endocrinology: medical consequences of doping with anabolic androgenic steroids: effects on reproductive functions. Eur J Endocrinol 173, R47-R58.
Niewoehner CB & Nuttal FQ. (1984) Gynecomastia in a hospitalized male population. Am J Med 77, 633-638.
Nuttall F. (1979) Gynecomastia as a physical finding in normal men. J Clin Endocrinol Metab 48, 338-340.
Nuttall F, Warrier R & Gannon M. (2015) Gynecomastia and drugs: a critical evaluation of the literature. Eur J Clin Pharmacol 71, 569-578.
Nydick M, Bustos J, Dale JH & Rawson RW. (1961) Gynecomastia in adolescent boys. JAMA 178, 449-454.
Olivo J, Gordon GG, Rafii F & Southren AL. (1975) Estrogen metabolism in hyperthyroidism and in cirrhosis of the liver. Steroids 26, 47-56.
Olusi SO. (1980) Hyperprolactinaemia in patients with suspected cannabis-induced gynaecomastia. Lancet 1, 255.
Ordaz DL & Thompson JK. (2015) Gynecomastia and psychological functioning: a review of the literature. Body Image 15, 141-148.
Paris F, Gaspari L, Mbou F, Philibert P, Audran F, Morel Y, Biason-Lauber A & Sultan C. (2016) Endocrine and molecular investigations in a cohort of 25 adolescent males with prominent/persistent pubertal gynecomastia. Andrology 4, 263-269.
Perdonà S, Autorino R, De Placido S, D’Armiento M, Gallo A, Damiano R, Pingitore D, Gallo L, De Sio M, Bianco AR & Di Lorenzo G. (2005) Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. Lancet Oncol 6, 295-300.
Plourde PV, Reiter EO, Jou HC, Desrochers PE, Rubin SD, Bercu BB, Diamond FB & Backeljauw PF. (2004) Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 89, 4428-4433.
Priskorn L, Nordkap L, Bang AK, Krause M, Holmboe SA, Egeberg Palme DL, Winge SB, Mørup N, Carlsen E, Joensen UN, Blomberg Jensen M, Main KM, Juul A, Skakkebaek NE, Jensen TK & Jørgensen N. (2018) Average sperm count remains unchanged despite reduction in maternal smoking: results from a large cross-sectional study with annual investigations over 21 years. Hum Reprod 33, 998-1008.
Quigley CA, De BA, Marschke KB, el-Awady MK, Wilson EM & French FS. (1995) Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev 16, 271-321.
Rahmani S, Turton P, Shaaban A & Dall B. (2011) Overview of gynecomastia in the modern era and the leeds gynaecomastia investigation algorithm. Breast J 17, 246-255.
Rew L, Young C, Harrison T & Caridi R. (2015) A systematic review of literature on psychosocial aspects of gynecomastia in adolescents and young men. J Adolesc 43, 206-212.
Riepe FG, Baus I, Wiest S, Krone N, Sippell WG & Partsch C-J. (2004) Treatment of pubertal gynecomastia with the specific aromatase inhibitor anastrozole. Horm Res Paediatr 62, 113-118.
Rochefort H & Garcia M. (1983) The estrogenic and antiestrogenic activities of androgens in female target tissues. Pharmacol Ther 23, 193-216.
Sarkar A, Bain J, Bhattacharya D, Sawarappa R, Munian K, Dutta G, Naiyer GJ & Ahmad S. (2014) Role of combined circumareolar skin excision and liposuction in management of high grade gynaecomastia. J Cutan Aesthet Surg 7, 112-116.
Sasano H, Kimura M, Shizawa S, Kimura N & Nagura H. (1996) Aromatase and steroid receptors in gynecomastia and male breast carcinoma: an immunohistochemical study. J Clin Endocrinol Metab 81, 3063-3067.
Sattin RW, Roisin A, Kafrissen ME, Dugan JB & Farer LS. (1984) Epidemic of gynecomastia among illegal Haitian entrants. Public Health Rep 99, 504-510.
Schmidt IM. (2002) Gender difference in breast tissue size in infancy: correlation with serum estradiol. Pediatr Res 52, 682-686.
Schonfeld WA. (1962) Gynecomastia in adolescence: effect on body image and personality adaptation. Psychosom Med 24, 379-389.
Smith SR, Chhetri MK, Johanson AJ, Radfar N & Migeon CJ. (1975) The pituitary-gonadal axis in men with protein-calorie malnutrition. J Clin Endocrinol Metab 41, 60-69.
Stratakis CA, Vottero A, Brodie A, Kirschner LS, DeAtkine D, Lu Q, Yue W, Mitsiades CS, Flor AW & Chrousos GP. (1998) The aromatase excess syndrome is associated with feminization of both sexes and autosomal dominant transmission of aberrant P450 aromatase gene transcription. J Clin Endocrinol Metab 83, 1348-1357.
Swiglo BA, Murad MH, Schünemann HJ, Kunz R, Vigersky RA, Guyatt GH & Montori VM. (2008) A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab 93, 666-673.
Tinggaard J, Mieritz M, Sørensen K, Mouritsen A, Hagen CP, Aksglaede L, Wohlfahrt-Veje C & Juul A. (2012) The physiology and timing of male puberty. Curr Opin Endocrinol Diabetes Obes 19, 197-203.
Volpe CM, Raffetto JD, Collure DW, Hoover EL & Doerr RJ. (1999) Unilateral male breast masses: cancer risk and their evaluation and management. Am Surg 65, 250-253.
Webster MH. (1980) Plastic surgery of the breast. Practitioner 224, 406-408.
Williams MJ. (1963) Gynecomastia. Its incidence, recognition and host characterization in 447 autopsy cases. Am J Med 34, 103-112.
Wu FC, Farley TM, Peregoudov A & Waites GM. (1996) Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Fertil Steril 65, 626-636.
Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD & EMAS Group. (2010) Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 363, 123-135.
Yu X-F, Yang H-J, Yu Y, Zou D-H & Miao L-L. (2015) A prognostic analysis of male breast cancer (MBC) compared with post-menopausal female breast cancer (FBC). PLoS ONE 10, e0136670.